SG10201509324QA - Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof - Google Patents

Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof

Info

Publication number
SG10201509324QA
SG10201509324QA SG10201509324QA SG10201509324QA SG10201509324QA SG 10201509324Q A SG10201509324Q A SG 10201509324QA SG 10201509324Q A SG10201509324Q A SG 10201509324QA SG 10201509324Q A SG10201509324Q A SG 10201509324QA SG 10201509324Q A SG10201509324Q A SG 10201509324QA
Authority
SG
Singapore
Prior art keywords
methods
amide compounds
deacetylase inhibitors
hydroxy amide
protein deacetylase
Prior art date
Application number
SG10201509324QA
Other languages
English (en)
Inventor
Duzer John H Van
Ralph Mazitschek
Yanbing Ding
Nan Yu
Yun Cao
Yong Liu
Original Assignee
Acetylon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46047943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201509324Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acetylon Pharmaceuticals Inc filed Critical Acetylon Pharmaceuticals Inc
Publication of SG10201509324QA publication Critical patent/SG10201509324QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
SG10201509324QA 2010-11-16 2011-11-15 Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof SG10201509324QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41415810P 2010-11-16 2010-11-16
US201161503286P 2011-06-30 2011-06-30

Publications (1)

Publication Number Publication Date
SG10201509324QA true SG10201509324QA (en) 2015-12-30

Family

ID=46047943

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013035498A SG190211A1 (en) 2010-11-16 2011-11-15 Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
SG10201509324QA SG10201509324QA (en) 2010-11-16 2011-11-15 Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013035498A SG190211A1 (en) 2010-11-16 2011-11-15 Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof

Country Status (20)

Country Link
US (3) US8614223B2 (ru)
EP (2) EP2640709B1 (ru)
JP (2) JP6041808B2 (ru)
KR (1) KR20130115300A (ru)
CN (2) CN103429574B (ru)
AU (2) AU2011329028B2 (ru)
BR (1) BR112013011868A2 (ru)
CA (1) CA2818125A1 (ru)
CL (1) CL2013001381A1 (ru)
EA (2) EA201691121A1 (ru)
ES (1) ES2568260T3 (ru)
HK (1) HK1189002A1 (ru)
IL (2) IL226326A0 (ru)
MX (1) MX2013005392A (ru)
NZ (2) NZ610225A (ru)
PH (1) PH12015500832A1 (ru)
PL (1) PL2640709T3 (ru)
PT (1) PT2640709T (ru)
SG (2) SG190211A1 (ru)
WO (1) WO2012068109A2 (ru)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012008553A (es) 2010-01-22 2012-11-30 Acetylon Pharmaceuticals Inc Compuestos de amida inversa como inhibidores de proteina desacetilasa y metodos de uso de los mismos.
CA2818125A1 (en) 2010-11-16 2012-05-24 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
AU2013234955A1 (en) 2012-03-23 2014-11-13 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
JP2015515279A (ja) 2012-04-19 2015-05-28 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療
WO2014059306A1 (en) * 2012-10-12 2014-04-17 The Trustees Of The University Of Pennsylvania Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
EP2968207A4 (en) * 2013-03-14 2016-09-28 Chdi Foundation Inc HISTON DEACETYLASE INHIBITORS AND COMPOSITIONS
EP2968233A4 (en) 2013-03-14 2016-08-03 Chdi Foundation Inc HISTON DEACETYLASE HEMMER AND COMPOSITIONS AND METHOD FOR USE THEREOF
US20160228434A1 (en) * 2013-09-20 2016-08-11 Acetylon Pharmaceuticals, Inc. Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitor
US9403779B2 (en) * 2013-10-08 2016-08-02 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors
JP6584391B2 (ja) * 2013-10-10 2019-10-02 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｐｉ３ｋ阻害剤との組み合わせ
US9278963B2 (en) * 2013-10-10 2016-03-08 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
WO2015054197A1 (en) * 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
CR20160200A (es) * 2013-10-11 2016-08-29 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
EA201691155A1 (ru) * 2013-12-03 2016-09-30 Эситайлон Фармасьютикалз, Инк. Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
ES2936812T3 (es) 2013-12-20 2023-03-22 Acetylon Pharmaceuticals Inc Biomarcadores de histona desacetilasa 6 (HDAC6) en mieloma múltiple
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
CN104974108B (zh) * 2014-04-04 2017-11-17 中国科学院上海药物研究所 一类2,2’‑串联双噻唑类化合物及其制备方法和用途
JP6600319B2 (ja) 2014-06-02 2019-10-30 シーエイチディーアイ ファウンデーション，インコーポレーテッド ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
BR112017000301A2 (pt) * 2014-07-07 2017-11-07 Acetylon Pharmaceuticals Inc tratamento de leucemia com inibidores de histona desacetilase
EP3226903A1 (en) 2014-12-05 2017-10-11 University of Modena and Reggio Emila Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma
US20160158231A1 (en) * 2014-12-05 2016-06-09 Vib Vzw Pyrimidine hydroxy amide compounds for treating peripheral neuropathy
JP6693957B2 (ja) 2014-12-12 2020-05-13 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｈｄａｃ１／２阻害剤としてのピペリジン誘導体
CN104503831B (zh) * 2014-12-22 2017-10-13 北京奇虎科技有限公司 设备优化方法及装置
AR103598A1 (es) 2015-02-02 2017-05-24 Forma Therapeutics Inc Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac
EP3292116B8 (en) 2015-02-02 2021-11-24 Valo Health, Inc. 3-aryl-4-amido-bicyclic [4,5,0]hydroxamic acids as hdac inhibitors
EP3287459B1 (en) * 2015-04-21 2020-09-02 Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd. Purinyl-n-hydroxyl pyrimidine formamide derivatives, preparation method therefor and use thereof
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
JP6816036B2 (ja) 2015-06-08 2021-01-20 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストン脱アセチル化阻害剤の結晶形態
AR105812A1 (es) 2015-06-08 2017-11-15 Acetylon Pharmaceuticals Inc Métodos para la preparación de inhibidores de proteína deacetilasa
WO2017075192A1 (en) * 2015-10-27 2017-05-04 Acetylon Pharmaceuticals, Inc. Hdac inhibitors for the treatment of diabetic peripheral neuropathy
WO2017184774A1 (en) 2016-04-19 2017-10-26 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia
KR20190021309A (ko) * 2016-06-07 2019-03-05 더마반트 사이언시즈 게엠베하 Pde-4 억제제의 국소 제제 및 그의 사용 방법
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
ES2929032T3 (es) 2016-08-08 2022-11-24 Acetylon Pharmaceuticals Inc Combinaciones farmacéuticas de inhibidores de histona desacetilasa 6 y anticuerpos inhibidores de CD20 y usos de los mismos
EP3538084B1 (en) * 2016-11-10 2023-11-01 Acetylon Pharmaceuticals, Inc. Phenyl and pyridinyl hydroxamic acids
WO2018098168A1 (en) 2016-11-23 2018-05-31 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereof
US10745389B2 (en) * 2017-01-10 2020-08-18 Cstone Pharmaceuticals (Suzhou) Co., Ltd. HDAC6 selective inhibitors, preparation method therefor, and application thereof
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
US11207431B2 (en) * 2017-04-11 2021-12-28 The General Hospital Corporation HDAC6 inhibitors and imaging agents
IT201700041723A1 (it) * 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6
KR102236356B1 (ko) * 2017-11-24 2021-04-05 주식회사 종근당 루푸스의 예방 또는 치료를 위한 조성물
CN108299313B (zh) * 2018-01-16 2020-10-02 长沙霍滋生物科技有限公司 一种化合物及其在药学上的应用
CN108129367B (zh) * 2018-02-05 2020-10-02 南开大学 一种构建手性亚磺酰亚胺α位手性四级碳的构建方法及其产品与应用
KR20190099952A (ko) * 2018-02-20 2019-08-28 주식회사 종근당 포도막염의 예방 또는 치료를 위한 조성물
US11345682B2 (en) 2018-07-04 2022-05-31 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Polymorph of HDAC6-selective inhibitor and application thereof
KR20200041812A (ko) * 2018-10-12 2020-04-22 주식회사 종근당 히스톤 탈아세틸화 효소 억제제 및 메토트렉세이트를 포함하는 약학적 조성물
CN111848454B (zh) * 2019-04-28 2021-05-07 山东大学 一种组蛋白去乙酰化酶6抑制剂及其制备方法和应用
WO2021110121A1 (zh) * 2019-12-05 2021-06-10 基石药业（苏州）有限公司 Hdac6选择性抑制剂及其组合疗法
CN112029738B (zh) * 2020-08-18 2022-04-29 浙江省人民医院 人parkin蛋白乙酰化及其在药物制备中的应用
CN113024536B (zh) * 2021-03-12 2022-05-27 湖南师范大学 含嘧啶-哌嗪环的5-氨基噻唑甲酰胺类化合物及其制备方法和用途
WO2023150203A1 (en) * 2022-02-03 2023-08-10 Eikonizo Therapeutics, Inc. Hdac6 inhibitors and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549633A (en) * 1968-11-20 1970-12-22 Merck & Co Inc Process for preparation of 1-h-imidazo (4,5-b)pyrazin-2-ones
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6231600B1 (en) 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
ZA9710342B (en) 1996-11-25 1998-06-10 Alza Corp Directional drug delivery stent and method of use.
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US5891507A (en) 1997-07-28 1999-04-06 Iowa-India Investments Company Limited Process for coating a surface of a metallic stent
US6153252A (en) 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US6248127B1 (en) 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6203551B1 (en) 1999-10-04 2001-03-20 Advanced Cardiovascular Systems, Inc. Chamber for applying therapeutic substances to an implant device
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
IL161661A0 (en) 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Amide derivatives as glycogen synthase kinase 3-beta inhibitors
US6517889B1 (en) 2001-11-26 2003-02-11 Swaminathan Jayaraman Process for coating a surface of a stent
DK1485354T3 (da) * 2002-03-13 2008-09-01 Janssen Pharmaceutica Nv Sulfonylamino-derivater som nye inhibitorer af histandeacetylase
DK1485353T3 (da) * 2002-03-13 2011-11-28 Janssen Pharmaceutica Nv Nye inhibitorer af histondeacetylase
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
PE20040801A1 (es) * 2002-12-12 2004-11-25 Hoffmann La Roche Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
ES2279395T3 (es) * 2003-07-24 2007-08-16 Basf Aktiengesellschaft Pirimidinas 2-substituidas.
CA2539117A1 (en) * 2003-09-24 2005-04-07 Methylgene Inc. Inhibitors of histone deacetylase
US8227636B2 (en) 2004-04-05 2012-07-24 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
CA2601706C (en) 2005-03-22 2016-09-20 Dana-Farber Cancer Institute, Inc. Treatment of protein degradation disorders
GB0510204D0 (en) * 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
AU2006284403A1 (en) * 2005-08-26 2007-03-01 Methylgene Inc. Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
WO2007091703A1 (en) * 2006-02-07 2007-08-16 Astellas Pharma Inc. N-hydroxyacrylamide compounds
JP5441416B2 (ja) 2006-02-14 2014-03-12 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二官能性ヒストンデアセチラーゼインヒビター
US8304451B2 (en) 2006-05-03 2012-11-06 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
CA2667826C (en) * 2006-10-28 2013-10-08 Methylgene Inc. Inhibitors of histone deacetylase
CN101918389A (zh) * 2007-11-02 2010-12-15 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
WO2009137503A1 (en) * 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Hdac inhibitors and uses thereof
WO2009137462A2 (en) * 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Methods for treating cognitive disorders using inhibitors of histone deacetylase
US8124764B2 (en) * 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
JP5665740B2 (ja) 2008-07-23 2015-02-04 プレジデント アンド フェローズ オブ ハーバード カレッジ デアセチラーゼ阻害剤およびその使用
CN102341108B (zh) * 2009-01-08 2015-05-27 柯瑞斯公司 具有锌结合半族的磷酸肌醇3-激酶抑制剂
US8309190B2 (en) 2009-02-26 2012-11-13 Arkema Inc. Rotational molded article formed from high molecular weight polyamides
ES2736200T3 (es) * 2009-07-22 2019-12-26 Univ Illinois Inhibidores de HDAC y métodos terapéuticos que utilizan los mismos
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
EP2638009A4 (en) 2010-01-08 2014-06-11 Harvard College FLUORINATED HDAC HEMMER AND USES THEREOF
MX2012008553A (es) 2010-01-22 2012-11-30 Acetylon Pharmaceuticals Inc Compuestos de amida inversa como inhibidores de proteina desacetilasa y metodos de uso de los mismos.
WO2012018499A2 (en) * 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
CA2818125A1 (en) * 2010-11-16 2012-05-24 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
EP2524918A1 (en) * 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
JP2015515279A (ja) 2012-04-19 2015-05-28 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
EP2951153B1 (en) 2013-02-01 2019-04-03 Regenacy Pharmaceuticals, LLC Selective hdac3 inhibitors
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
WO2014197471A1 (en) 2013-06-03 2014-12-11 Acetylon Pharmaceuticals, Inc. Histone deacetylase ( hdac) biomarkers in multiple myeloma
US9403779B2 (en) 2013-10-08 2016-08-02 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors
US9278963B2 (en) 2013-10-10 2016-03-08 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
JP6584391B2 (ja) 2013-10-10 2019-10-02 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｐｉ３ｋ阻害剤との組み合わせ
WO2015054197A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
CR20160200A (es) 2013-10-11 2016-08-29 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores
EA201691155A1 (ru) 2013-12-03 2016-09-30 Эситайлон Фармасьютикалз, Инк. Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств

Also Published As

Publication number Publication date
CN103429574A (zh) 2013-12-04
MX2013005392A (es) 2013-07-29
PL2640709T3 (pl) 2016-10-31
NZ610225A (en) 2015-08-28
CL2013001381A1 (es) 2014-04-11
EA201691121A1 (ru) 2016-10-31
PH12015500832A1 (en) 2015-10-19
US9409890B2 (en) 2016-08-09
WO2012068109A2 (en) 2012-05-24
JP2013542994A (ja) 2013-11-28
JP2017019820A (ja) 2017-01-26
AU2011329028A1 (en) 2013-05-30
ES2568260T3 (es) 2016-04-28
IL249594A0 (en) 2017-02-28
US20120121502A1 (en) 2012-05-17
CN103429574B (zh) 2016-11-16
CA2818125A1 (en) 2012-05-24
EA025345B1 (ru) 2016-12-30
PT2640709T (pt) 2016-07-13
WO2012068109A3 (en) 2012-08-02
EP2640709A4 (en) 2014-04-02
CN107011270A (zh) 2017-08-04
US20170096403A1 (en) 2017-04-06
NZ710405A (en) 2017-04-28
AU2011329028B2 (en) 2016-12-22
US20140142104A1 (en) 2014-05-22
EP3067346A1 (en) 2016-09-14
EP2640709B1 (en) 2016-04-06
BR112013011868A2 (pt) 2016-08-23
JP6041808B2 (ja) 2016-12-14
HK1189002A1 (zh) 2014-05-23
SG190211A1 (en) 2013-06-28
KR20130115300A (ko) 2013-10-21
US8614223B2 (en) 2013-12-24
AU2016266069A1 (en) 2016-12-22
EP2640709A2 (en) 2013-09-25
EA201390711A1 (ru) 2014-03-31
IL226326A0 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
IL249594A0 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
ZA201206063B (en) Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
HK1213471A1 (zh) 作為蛋白脫乙酰基酶抑制劑的嘧啶羥基酰胺化合物及其使用方法
HK1213769A1 (zh) 精氨酸酶抑制劑及其使用方法
EP2619184A4 (en) DEUBIQUITINASE INHIBITORS AND METHOD FOR THEIR USE
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
EP2590982A4 (en) PROTEIN INHIBITOR KINASES AND METHODS OF TREATMENT
ZA201206223B (en) Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
EP2539348A4 (en) CEPHALOSPORIN DERIVATIVES AS BETA LACTAMASE HEMMER AND COMPOSITIONS THEREFOR AND METHOD FOR THEIR USE
PT2389352T (pt) Inibidores de arginase e métodos de utilização
HK1179623A1 (en) Inhibitors of protein kinases
EP2536283A4 (en) PHENYLHETEROARYL DERIVATIVES AND USE METHOD THEREFOR
IL227379A0 (en) Histone deacetylase inhibitors and compositions and methods of using them
EP2536709A4 (en) PROLYLHYDROXYLASE INHIBITORS AND METHODS OF USE
EP2393787A4 (en) CADHERINE 11 INHIBITORS AND METHOD FOR THEIR USE
IL257069B (en) Inhibitors of cell death and uses thereof
ZA201301795B (en) Inhibitors of notum pectinacetylesterase and methods of their use
IL236686A0 (en) Inhibitors of histone deacetylase and compositions and methods of using them
GB201003949D0 (en) Inhibitors of protein kinases